21 March 2024, 6pm-9pm
SHED Zug, Dammstrasse 16, 6300 Zug
Prof. Dr. Roger M. Nitsch
CEO & President of the Board - Neurimmune
Roger Nitsch serves as CEO and President of Neurimmune which he founded in 2006 with two business partners. A neuroscience entrepreneur with a background in medicine, he is recognized as an opinion leader in drug development for neurodegenerative diseases with over 30 years of experience in Alzheimer’s disease research. A Potamkin Prize winner and Member of the German Academy of Sciences, Roger serves on the boards of LONZA, INTEGRA Biosciences and NovaGo, and on the advisory board of PUREOS Bioventures.
He holds an MD degree from the University of Heidelberg and earned his post-doctoral qualification at the Massachusetts Institute of Technology and Harvard Medical School.
Roger Nitsch serves as CEO and President of Neurimmune which he founded in 2006 with two business partners. A neuroscience entrepreneur with a background in medicine, he is recognized as an opinion leader in drug development for neurodegenerative diseases with over 30 years of experience in Alzheimer’s disease research. A Potamkin Prize winner and Member of the German Academy of Sciences, Roger serves on the boards of LONZA, INTEGRA Biosciences and NovaGo, and on the advisory board of PUREOS Bioventures.
He holds an MD degree from the University of Heidelberg and earned his post-doctoral qualification at the Massachusetts Institute of Technology and Harvard Medical School.
Roger Nitsch serves as CEO and President of Neurimmune which he founded in 2006 with two business partners. A neuroscience entrepreneur with a background in medicine, he is recognized as an opinion leader in drug development for neurodegenerative diseases with over 30 years of experience in Alzheimer’s disease research. A Potamkin Prize winner and Member of the German Academy of Sciences, Roger serves on the boards of LONZA, INTEGRA Biosciences and NovaGo, and on the advisory board of PUREOS Bioventures.
He holds an MD degree from the University of Heidelberg and earned his post-doctoral qualification at the Massachusetts Institute of Technology and Harvard Medical School.
Roger Nitsch serves as CEO and President of Neurimmune which he founded in 2006 with two business partners. A neuroscience entrepreneur with a background in medicine, he is recognized as an opinion leader in drug development for neurodegenerative diseases with over 30 years of experience in Alzheimer’s disease research. A Potamkin Prize winner and Member of the German Academy of Sciences, Roger serves on the boards of LONZA, INTEGRA Biosciences and NovaGo, and on the advisory board of PUREOS Bioventures.
He holds an MD degree from the University of Heidelberg and earned his post-doctoral qualification at the Massachusetts Institute of Technology and Harvard Medical School.
This "by invitation only" event, which has been held for several years, has become a very successful and sought-after event within the Healthcare community in and around the Zug area. Due to the great success and ever increasing demand, we have decided to hold the event two or three times a year. If you are interested in becoming a sponsoring partner, please contact us.
Please note that this is a "by invitation only" event. Should you not have a token, please contact jennifer.toumi@hbmpartners.com.
Bundesplatz 1 | 6300 Zug | Phone: +41 43 888 71 18 | jennifer.toumi@hbmpartners.com